Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylate cyclase type 8 (ADCY8)
- Target
- ADCY8
- Molecular classification
- Enzyme, Adenylate cyclase family, Membrane-associated protein
01
Overview
Adenylate cyclase type 8 (ADCY8) is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP) in response to increases in intracellular calcium, integrating Ca²⁺ and cAMP signaling. ADCY8 is highly expressed in neurons, specifically at synaptic sites, and plays a key role in synaptic plasticity, learning, memory, and modulation of neuronal signaling. In the pancreas, ADCY8 is a critical component for glucose-stimulated cAMP production and insulin secretion. ADCY8 is regulated by G protein-coupled receptors and Ca²⁺/calmodulin, and its dysfunction has been linked to neurological and metabolic diseases, including anxiety, dissociative amnesia, and impaired insulin secretion in diabetes.
- Other names
- AC8Adenylate cyclase 8 (brain)Ca(2+)/calmodulin-activated adenylyl cyclaseATP pyrophosphate-lyase 8Adenylyl cyclase 8Adenylate cyclase type VIIIHBAC1
02
Mechanism of action
Drugs targeting the cAMP pathway may indirectly modulate ADCY8 activity by affecting upstream (G protein-coupled receptors) or downstream (protein kinase A, CREB) signaling
03
Biological functions
Signal transduction (conversion of ATP to cAMP)Synaptic plasticity (neuronal signaling)Calcium signaling (coupling Ca²⁺ influx to cAMP synthesis)Regulation of insulin secretion in pancreatic β-cells
04
Disease associations
Neurodegenerative disease (involved in learning, memory, anxiety modulation, addiction)Metabolic disorders (impaired incretin signaling, reduced insulin secretion)Other: Dissociative amnesia, anxiety
05
Safety considerations
Off-target effects on central nervous system and metabolic functions due to ADCY8’s broad role in neuronal signaling and insulin secretion
06
Interacting drugs
No directly approved drugs known to target ADCY8 specifically; however, downstream pathways (e.g., cAMP modulators, incretin mimetics) are targeted in therapeutics
07
Biomarkers
cAMP levels (as indirect measure of ADCY8 activity)Expression of synaptic proteins for neurological disorders
Beyond the preview
Go deeper on Adenylate cyclase type 8 (ADCY8).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenylate cyclase type 8 (ADCY8).